Detalhe da pesquisa
1.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
N Engl J Med
; 389(16): 1453-1465, 2023 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851874
2.
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740030
3.
Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy.
Prostate
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685667
4.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285865
5.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Oncologist
; 29(3): 235-243, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37812679
6.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394384
7.
A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
J Urol
; : 101097JU0000000000003991, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700731
8.
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-up From a Phase 3 Trial.
J Urol
; : 101097JU0000000000004020, 2024 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704840
9.
Complications of immuno-oncology care: what urologist should know.
BJU Int
; 133(5): 524-531, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437876
10.
Updates on Management of Biochemical Recurrent Prostate Cancer.
Curr Treat Options Oncol
; 25(3): 284-292, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286895
11.
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Future Oncol
; 20(9): 493-505, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882449
12.
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Future Oncol
; 20(14): 891-901, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189180
13.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(10): 1094-1108, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37714168
14.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
N Engl J Med
; 382(23): 2187-2196, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469183
15.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med
; 383(11): 1040-1049, 2020 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32905676
16.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32955174
17.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469184
18.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(22): 2091-2102, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32343890
19.
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
J Urol
; 209(3): 532-539, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36756959
20.
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
J Urol
; 210(4): 619-629, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548555